*INVITE* KOL call:Congress restricting China clinical data use? 5/12@10:30AM ET

Research evidence excerpt

*INVITE* KOL call:Congress restricting China clinical data use? 5/12@10:30AM ET

USA | Biotechnology EquityMayResearch11, 2026

*INVITE* KOL call:Congress restricting China

clinical data use? 5/12@10:30AM ET

Please Join Akash Tewari and KOL Haroon Cheema tomorrow (Tuesday,

May 12), at 10:30AM ET as they discuss the potential legislative path

and implications of the amendment proposed by Rep. Andy Harris to

the Agricultural/Rural/FDA Appropriation Subcommittee Bill, calling for the

prohibition of using the clinical data generated in China for NDA in the US

**Please click HERE to register**

Background of the topic: Rep. Andy Harris has proposed an amendment to the Agricultural/Rural/

FDA Appropriation Subcommittee Bill, calling for prohibition of using the clinical data generated in

China for NDA in the US (“….prohibits FDA from accepting, reviewing, or considering any covered

clinical data generated by a clinical investigation site located in a covered nation as defined in 10

U.S.C. 4872(f) in support of an investigational new drug application under section 505 of the Federal

Food, Drug, and Cosmetic Act (21 U.S.C. 355) or section 351 of the Public Health Service Act (42

U.S.C. 262), including any amendment or supplement thereto”).

KOL Biography: Mr. Haroon Cheema is the Co-Owner & Chief Financial Officer at SAXA Equity

Partners, LLC (11/2008 - Present). He advises financial services and emerging technology

companies on strategy, capital structuring, financial modelling, and regulatory compliance. He has

supported businesses from formation through scale, including fundraising across private markets,

structuring SPVs (including crypto/NFT vehicles), and managing investor and government relations.

He is also currently a Principal at Timpani Global LLC (05/2017 - Present).